258 related articles for article (PubMed ID: 3814832)
1. Refractory cytopenias: clinical course according to bone marrow cytology and cellularity.
Riccardi A; Giordano M; Girino M; Cazzola M; Montecucco CM; Cassano E; Danova M; Ucci G; Castello A; Coci A
Blut; 1987 Mar; 54(3):153-63. PubMed ID: 3814832
[TBL] [Abstract][Full Text] [Related]
2. Hypoplastic myelodysplastic syndrome.
Nand S; Godwin JE
Cancer; 1988 Sep; 62(5):958-64. PubMed ID: 3409176
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes.
Jacobs RH; Cornbleet MA; Vardiman JW; Larson RA; Le Beau MM; Rowley JD
Blood; 1986 Jun; 67(6):1765-72. PubMed ID: 3708160
[TBL] [Abstract][Full Text] [Related]
4. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
[TBL] [Abstract][Full Text] [Related]
6. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of dysplastic changes in acquired aplastic anemia: A systematic study of bone marrow biopsies in children and adults.
Marchesi RF; Velloso EDRP; Garanito MP; Leal AM; Siqueira SAC; Azevedo Neto RS; Rocha V; Zerbini MCN
Ann Diagn Pathol; 2020 Apr; 45():151459. PubMed ID: 32000075
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases.
Foucar K; Langdon RM; Armitage JO; Olson DB; Carroll TJ
Cancer; 1985 Aug; 56(3):553-61. PubMed ID: 3891071
[TBL] [Abstract][Full Text] [Related]
10. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome.
Sato T; Kim S; Selleri C; Young NS; Maciejewski JP
Leukemia; 1998 Aug; 12(8):1187-94. PubMed ID: 9697872
[TBL] [Abstract][Full Text] [Related]
11. Life expectancy in primary myelodysplastic syndromes: a prognostic score based upon histopathology from bone marrow biopsies of 569 patients.
Maschek H; Gutzmer R; Choritz H; Georgii A
Eur J Haematol; 1994 Nov; 53(5):280-7. PubMed ID: 7813708
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome.
Shih LY; Chiu WF; Lee CT
Leukemia; 1991 Dec; 5(12):1092-8. PubMed ID: 1774958
[TBL] [Abstract][Full Text] [Related]
13. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
15. Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome.
Aoki I; Higashi K; Homori M; Chikazawa H; Ishikawa K
Am J Hematol; 1990 Sep; 35(1):6-12. PubMed ID: 2389770
[TBL] [Abstract][Full Text] [Related]
16. Hypocellular myelodysplastic syndromes: clinical and biological significance.
Marisavljevic D; Cemerikic V; Rolovic Z; Boskovic D; Colovic M
Med Oncol; 2005; 22(2):169-75. PubMed ID: 15965280
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
[TBL] [Abstract][Full Text] [Related]
18. Hypocellular myelodysplastic syndromes (MDS): new proposals.
Tuzuner N; Cox C; Rowe JM; Watrous D; Bennett JM
Br J Haematol; 1995 Nov; 91(3):612-7. PubMed ID: 8555063
[TBL] [Abstract][Full Text] [Related]
19. Proposals for the classification of the myelodysplastic syndromes.
Bennett JM; Catovsky D; Daniel MT; Flandrin G; Galton DA; Gralnick HR; Sultan C
Br J Haematol; 1982 Jun; 51(2):189-99. PubMed ID: 6952920
[TBL] [Abstract][Full Text] [Related]
20. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes.
Baur AS; Meugé-Moraw C; Schmidt PM; Parlier V; Jotterand M; Delacrétaz F
Eur J Haematol; 2000 Feb; 64(2):71-9. PubMed ID: 10997326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
